Ixazomib

NINLARO®

Overview

Ninlaro® (ixazomib) is an oral proteasome inhibitor that was approved by the FDA in the fall of 2016 to treat multiple myeloma in combination with the medicines lenalidomide and dexamethasone, in people who have received at least one prior treatment for their multiple myeloma. It may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

SparkCures ID 36
Developed By Takeda Oncology
Brand Name Ninlaro®
Generic Name Ixazomib
Additional Names MLN9708
Treatment Classifications
Tags
  • FDA Approved

Clinical Trials

All Clinical Trials

View all active clinical trials around the US.

Untreated / Newly Diagnosed Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have been newly diagnosed or have not yet received treatment.

Early Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.

Late Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.

Smoldering Myeloma

The following is a listing of clinical trials for patients with Smoldering Myeloma.

Monoclonal Gammopathy of Undetermined Significance (MGUS)

Resources